{"transactions":[{"id":729233,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-23T20:07:02.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":57463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029."}],"balance_after":57463,"derivative":{"exercise_price":20.87,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":57463},"source":{"system":"sec-edgar","filing":"0001291963-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000129196326000008/ownership.xml","form_type":"4"}},{"id":763521,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T20:06:23.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":15508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted stock units (\"RSUs\") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025."}],"balance_after":16415,"source":{"system":"sec-edgar","filing":"0001291963-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000129196326000004/ownership.xml","form_type":"4"}},{"id":1078303,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-31T15:17:47.000Z","date":"2025-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":174000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.97,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":174000},"source":{"system":"sec-edgar","filing":"0000950170-25-100636","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000095017025100636/ownership.xml","form_type":"4"}},{"id":1078302,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-31T15:17:47.000Z","date":"2025-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":53229,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-100636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000095017025100636/ownership.xml","form_type":"4"}},{"id":1078301,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-31T15:17:47.000Z","date":"2025-07-31","kind":"other","planned":false,"acquired":false,"shares":46940,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-100636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000095017025100636/ownership.xml","form_type":"4"}},{"id":1130397,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-05-29T20:08:28.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 100% of the underlying shares on May 28, 2026."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025."}],"balance_after":4600,"derivative":{"exercise_price":4.48,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":4600},"source":{"system":"sec-edgar","filing":"0000950170-25-078944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000095017025078944/ownership.xml","form_type":"4"}},{"id":1173238,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-04-11T20:09:39.000Z","date":"2025-04-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":4862,"price":6.91,"value":33596.42,"ownership":{"direct":true},"balance_after":100169,"source":{"system":"sec-edgar","filing":"0001562180-25-003112","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218025003112/primarydocument.xml","form_type":"4"}},{"id":1173237,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-04-11T20:09:39.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":19964,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 11, 2022, the reporting person was granted Performance Restricted Stock Units (PSUs) to acquire a total of 57,040 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on April 10, 2025, resulting in the vesting of the PSUs as to 19,964 shares."}],"balance_after":105031,"source":{"system":"sec-edgar","filing":"0001562180-25-003112","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218025003112/primarydocument.xml","form_type":"4"}},{"id":1298653,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-21T21:11:46.000Z","date":"2025-01-16","kind":"grant","planned":false,"acquired":true,"shares":174000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on January 16, 2025 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Options to purchase 43,500 shares of common stock shall vest on the one year anniversary of January 16, 2025, with 130,500 shares vesting in 36 equal monthly installments thereafter."}],"balance_after":174000,"derivative":{"exercise_price":6.97,"expiration_date":"2035-01-16","underlying":"Common Stock","underlying_shares":174000},"source":{"system":"sec-edgar","filing":"0001562180-25-000437","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218025000437/primarydocument.xml","form_type":"4"}},{"id":1438684,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-07T20:05:24.000Z","date":"2024-08-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":12273,"price":8.96,"value":109966.08,"ownership":{"direct":true},"balance_after":85067,"source":{"system":"sec-edgar","filing":"0001562180-24-006090","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218024006090/primarydocument.xml","form_type":"4"}},{"id":1438683,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-07T20:05:24.000Z","date":"2024-08-05","kind":"grant","planned":false,"acquired":true,"shares":50400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 13, 2024, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 126,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on August 5, 2024, resulting in the vesting of the PSUs as to 50,400 shares."}],"balance_after":97340,"source":{"system":"sec-edgar","filing":"0001562180-24-006090","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218024006090/primarydocument.xml","form_type":"4"}},{"id":1497687,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2024-05-30T21:25:11.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on May 29, 2025."}],"balance_after":69000,"derivative":{"exercise_price":0.96,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":69000},"source":{"system":"sec-edgar","filing":"0000950170-24-066781","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000095017024066781/ownership.xml","form_type":"4"}},{"id":1640796,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:02:52.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":168000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on February 13, 2024 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 42,000 shares of common stock shall vest on the one year anniversary of February 13, 2024, with 126,000 shares vesting in 36 equal monthly installments thereafter."}],"balance_after":168000,"derivative":{"exercise_price":23.02,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001562180-24-001336","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218024001336/primarydocument.xml","form_type":"4"}},{"id":1812832,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-08T20:15:55.000Z","date":"2023-08-04","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 4, 2021, the reporting person was granted an option to purchase 650,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on August 4, 2023, resulting in the vesting of the option as to 195,000 shares."}],"balance_after":195000,"derivative":{"exercise_price":85.82,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001562180-23-006237","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218023006237/primarydocument.xml","form_type":"4"}},{"id":1877872,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2023-05-25T20:04:18.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on May 24, 2024."}],"balance_after":34000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-23-032137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919123032137/doc4.xml","form_type":"4"}},{"id":2013396,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T21:46:27.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":66500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 16,625 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 49,875 shares vesting in 36 equal monthly installments thereafter."}],"balance_after":66500,"derivative":{"exercise_price":45.28,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":66500},"source":{"system":"sec-edgar","filing":"0001562180-23-001422","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218023001422/primarydocument.xml","form_type":"4"}},{"id":2115968,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-11-15T21:04:20.000Z","date":"2022-11-10","kind":"purchase","acquired":true,"shares":14500,"price":34.4843,"value":500022.35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $34.19 USD to $34.86 USD. The price reported above reflects the weighted average purchase price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":46940,"source":{"system":"sec-edgar","filing":"0001562180-22-007667","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218022007667/primarydocument.xml","form_type":"4"}},{"id":2185482,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-15T12:05:50.000Z","date":"2022-08-11","kind":"exercise","acquired":false,"shares":7576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 14, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":1.485,"expiration_date":"2023-01-20","underlying":"Common Stock","underlying_shares":7576},"source":{"system":"sec-edgar","filing":"0001209191-22-045718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919122045718/doc4.xml","form_type":"4"}},{"id":2185481,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T12:05:50.000Z","date":"2022-08-11","kind":"exercise","acquired":true,"shares":7576,"price":1.485,"value":11250.36,"ownership":{"direct":true},"balance_after":13606,"source":{"system":"sec-edgar","filing":"0001209191-22-045718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919122045718/doc4.xml","form_type":"4"}},{"id":2261637,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2022-05-20T20:02:28.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":23900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc."}],"balance_after":23900,"derivative":{"exercise_price":5.65,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":23900},"source":{"system":"sec-edgar","filing":"0001209191-22-030953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919122030953/doc4.xml","form_type":"4"}},{"id":2394209,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:42:41.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":69920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on February 11, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 17,480 shares of common stock shall vest on the one year anniversary of February 11, 2022, with 52,440 shares vesting in 36 equal monthly installments thereafter."}],"balance_after":69920,"derivative":{"exercise_price":43.04,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":69920},"source":{"system":"sec-edgar","filing":"0001562180-22-001477","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218022001477/primarydocument.xml","form_type":"4"}},{"id":2609919,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-09T13:07:53.000Z","date":"2021-08-05","kind":"purchase","acquired":true,"shares":23640,"price":43.1495,"value":1020054.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $42.66 USD to $43.46 USD. The price reported above reflects the weighted average purchase price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":32440,"source":{"system":"sec-edgar","filing":"0001562180-21-005226","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218021005226/primarydocument.xml","form_type":"4"}},{"id":2663345,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-06-17T13:14:33.000Z","date":"2021-06-16","kind":"purchase","acquired":true,"shares":8800,"price":56.3213,"value":495627.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $56.12 USD to $56.41 USD. The price reported above reflects the weighted average purchase price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":8800,"source":{"system":"sec-edgar","filing":"0001562180-21-004342","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218021004342/primarydocument.xml","form_type":"4"}},{"id":2681601,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option","published_at":"2021-06-04T07:11:27.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 2, 2021, with the first quarterly installment vesting on September 2, 2021."}],"balance_after":10000,"derivative":{"exercise_price":3.75,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-038106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919121038106/doc4.xml","form_type":"4"}},{"id":2700649,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2021-05-21T21:33:40.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":23900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the \"Issuer\"), provided that the reporting person continues to serve as a director of the Issuer through such date."}],"balance_after":23900,"derivative":{"exercise_price":9.42,"expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":23900},"source":{"system":"sec-edgar","filing":"0001209191-21-035026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919121035026/doc4.xml","form_type":"4"}},{"id":2915171,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to buy)","published_at":"2021-01-06T21:22:25.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":390000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on January 4, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 97,500 shares of common stock shall vest on the one year anniversary of January 4, 2021, with 292,500 shares vesting in 36 equal monthly installments thereafter, so long as the Reporting Person remains an employee or consultant of the Company on each of the applicable vesting dates."}],"balance_after":390000,"derivative":{"exercise_price":85.82,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":390000},"source":{"system":"sec-edgar","filing":"0001562180-21-000188","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218021000188/primarydocument.xml","form_type":"4"}},{"id":3012914,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-10-05T20:43:17.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to the option vest in equal monthly installments during the 36 months following October 1, 2020 (the \"Grant Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date, subject to the reporting person's continued service as a director of the issuer through such date."}],"balance_after":20000,"derivative":{"exercise_price":59.53,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-20-006284","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000156218020006284/primarydocument.xml","form_type":"4"}},{"id":3033369,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2020-09-11T21:11:05.000Z","date":"2020-09-09","kind":"exercise","acquired":false,"shares":44530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":9.14,"expiration_date":"2020-12-08","underlying":"Common Stock","underlying_shares":44530},"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033368,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-07-16","kind":"gift","acquired":false,"shares":3176,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033367,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-07-16","kind":"gift","acquired":false,"shares":155,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person."}],"balance_after":3176,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033366,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-07-16","kind":"gift","acquired":false,"shares":155,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person."}],"balance_after":3331,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033365,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-07-16","kind":"gift","acquired":true,"shares":155,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Dependent"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person."}],"balance_after":155,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033364,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-09-09","kind":"sale","acquired":false,"shares":3346,"price":124.38,"value":416175.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $124.03 to $124.87."}],"balance_after":70343,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033363,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-09-09","kind":"sale","acquired":false,"shares":27109,"price":123.39,"value":3344979.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $123.01 to $124.00."}],"balance_after":73689,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033362,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-09-09","kind":"sale","acquired":false,"shares":14075,"price":122.66,"value":1726439.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $122.00 to $123.00."}],"balance_after":100798,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033361,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-09-09","kind":"exercise","acquired":true,"shares":44530,"price":9.14,"value":407004.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 44,530 options exercised and sold by the reporting person were due to expire on December 8, 2020."}],"balance_after":114873,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3033360,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-09-11T21:11:05.000Z","date":"2020-07-16","kind":"gift","acquired":true,"shares":3176,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of ALNY common stock distributed upon termination of the Barry E. Greene Qualified Annuity Interest Trust (GRAT), of which the reporting person is the sole Trustee. Upon termination of the trust on July 16, 2020, 155 of the shares held by the GRAT were gifted to a non-dependent child, and 155 of the shares were transferred to the reporting persons dependent child. The remaining 3,176 shares were distributed to the reporting person."}],"balance_after":65412,"source":{"system":"sec-edgar","filing":"0001735276-20-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000098/edgardoc.xml","form_type":"4"}},{"id":3062138,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option  (right to buy)","published_at":"2020-08-11T20:09:06.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":1036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":46589,"derivative":{"exercise_price":96.45,"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":1036},"source":{"system":"sec-edgar","filing":"0001735276-20-000093","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000093/edgardoc.xml","form_type":"4"}},{"id":3062137,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option  (right to buy)","published_at":"2020-08-11T20:09:06.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":1124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":38876,"derivative":{"exercise_price":88.95,"expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":1124},"source":{"system":"sec-edgar","filing":"0001735276-20-000093","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000093/edgardoc.xml","form_type":"4"}},{"id":3062136,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option  (right to buy)","published_at":"2020-08-11T20:09:06.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":1587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":88413,"derivative":{"exercise_price":63,"expiration_date":"2023-12-18","underlying":"Common Stock","underlying_shares":1587},"source":{"system":"sec-edgar","filing":"0001735276-20-000093","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000093/edgardoc.xml","form_type":"4"}},{"id":3062135,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option  (right to buy)","published_at":"2020-08-11T20:09:06.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":1184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":23816,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":1184},"source":{"system":"sec-edgar","filing":"0001735276-20-000093","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000093/edgardoc.xml","form_type":"4"}},{"id":3062134,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-08-11T20:09:06.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":1184,"price":42.22,"value":49988.48,"ownership":{"direct":true},"balance_after":67167,"source":{"system":"sec-edgar","filing":"0001735276-20-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000093/edgardoc.xml","form_type":"4"}},{"id":3062133,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-08-11T20:09:06.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":1124,"price":88.95,"value":99979.8,"ownership":{"direct":true},"balance_after":65983,"source":{"system":"sec-edgar","filing":"0001735276-20-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000093/edgardoc.xml","form_type":"4"}},{"id":3062132,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-08-11T20:09:06.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":1036,"price":96.45,"value":99922.2,"ownership":{"direct":true},"balance_after":64859,"source":{"system":"sec-edgar","filing":"0001735276-20-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000093/edgardoc.xml","form_type":"4"}},{"id":3062131,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-08-11T20:09:06.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":1587,"price":63,"value":99981.0,"ownership":{"direct":true},"balance_after":63823,"source":{"system":"sec-edgar","filing":"0001735276-20-000093","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000093/edgardoc.xml","form_type":"4"}},{"id":3085787,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-09T20:02:15.000Z","date":"2020-07-07","kind":"exercise","acquired":false,"shares":22265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":44530,"derivative":{"exercise_price":9.14,"expiration_date":"2020-12-08","underlying":"Common Stock","underlying_shares":22265},"source":{"system":"sec-edgar","filing":"0001735276-20-000084","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000084/edgardoc.xml","form_type":"4"}},{"id":3085786,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-07-09T20:02:15.000Z","date":"2020-07-07","kind":"sale","acquired":false,"shares":22265,"price":159.99,"value":3562177.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020."}],"balance_after":62236,"source":{"system":"sec-edgar","filing":"0001735276-20-000084","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000084/edgardoc.xml","form_type":"4"}},{"id":3085785,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-07-09T20:02:15.000Z","date":"2020-07-07","kind":"exercise","acquired":true,"shares":22265,"price":9.14,"value":203502.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020."}],"balance_after":84501,"source":{"system":"sec-edgar","filing":"0001735276-20-000084","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000084/edgardoc.xml","form_type":"4"}},{"id":3107738,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option","published_at":"2020-06-17T16:55:02.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 15, 2020, with the first quarterly installment vesting on September 15, 2020."}],"balance_after":15000,"derivative":{"exercise_price":0.8512,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-037298","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919120037298/doc4.xml","form_type":"4"}},{"id":3134954,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2020-05-26T20:21:29.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":16400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on May 21, 2021, provided that the reporting person continues to serve as a director of the issuer through such date."}],"balance_after":16400,"derivative":{"exercise_price":19.11,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":16400},"source":{"system":"sec-edgar","filing":"0001209191-20-032007","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919120032007/doc4.xml","form_type":"4"}},{"id":3158230,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-07T20:09:32.000Z","date":"2020-05-06","kind":"exercise","acquired":false,"shares":22265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":66795,"derivative":{"exercise_price":9.14,"expiration_date":"2020-12-08","underlying":"Common Stock","underlying_shares":22265},"source":{"system":"sec-edgar","filing":"0001735276-20-000060","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000060/edgardoc.xml","form_type":"4"}},{"id":3158229,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-05-07T20:09:32.000Z","date":"2020-05-06","kind":"sale","acquired":false,"shares":22265,"price":149.99,"value":3339527.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020."}],"balance_after":62236,"source":{"system":"sec-edgar","filing":"0001735276-20-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000060/edgardoc.xml","form_type":"4"}},{"id":3158228,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-05-07T20:09:32.000Z","date":"2020-05-06","kind":"exercise","acquired":true,"shares":22265,"price":9.14,"value":203502.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020."}],"balance_after":84501,"source":{"system":"sec-edgar","filing":"0001735276-20-000060","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000060/edgardoc.xml","form_type":"4"}},{"id":3179109,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-04-09T20:06:02.000Z","date":"2020-04-07","kind":"tax_withholding","acquired":false,"shares":64,"price":106.65,"value":6825.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":62236,"source":{"system":"sec-edgar","filing":"0001735276-20-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000049/edgardoc.xml","form_type":"4"}},{"id":3179108,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-04-09T20:06:02.000Z","date":"2020-04-07","kind":"tax_withholding","acquired":false,"shares":1599,"price":104.75,"value":167495.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":62300,"source":{"system":"sec-edgar","filing":"0001735276-20-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000049/edgardoc.xml","form_type":"4"}},{"id":3179107,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2020-04-09T20:06:02.000Z","date":"2020-04-07","kind":"grant","acquired":true,"shares":5417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review.  This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020."}],"balance_after":63899,"source":{"system":"sec-edgar","filing":"0001735276-20-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000049/edgardoc.xml","form_type":"4"}},{"id":3204827,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-03-17T21:35:03.000Z","date":"2020-03-13","kind":"exercise","acquired":false,"shares":3030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option representing a right to purchase a specified number of shares vested as to 25% of the shares on April 14, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":0.033,"expiration_date":"2021-04-13","underlying":"Common Stock","underlying_shares":3030},"source":{"system":"sec-edgar","filing":"0001209191-20-019709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919120019709/doc4.xml","form_type":"4"}},{"id":3204826,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-17T21:35:03.000Z","date":"2020-03-13","kind":"exercise","acquired":true,"shares":3030,"price":0.033,"value":99.99,"ownership":{"direct":true},"balance_after":6030,"source":{"system":"sec-edgar","filing":"0001209191-20-019709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919120019709/doc4.xml","form_type":"4"}},{"id":3241489,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option  (right to buy)","published_at":"2020-02-28T21:06:11.000Z","date":"2020-02-26","kind":"grant","acquired":true,"shares":29925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2019. The reporting person also received 16,519 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":29925,"derivative":{"exercise_price":118.05,"expiration_date":"2030-02-25","underlying":"Common Stock","underlying_shares":29925},"source":{"system":"sec-edgar","filing":"0001735276-20-000029","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000029/edgardoc.xml","form_type":"4"}},{"id":3331432,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2017 (right to buy)","published_at":"2019-12-26T21:02:35.000Z","date":"2019-12-23","kind":"grant","acquired":true,"shares":9999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019."}],"balance_after":19998,"derivative":{"exercise_price":119.13,"exercise_date":"2019-12-23","expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":9999},"source":{"system":"sec-edgar","filing":"0001735276-19-000119","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000119/edgardoc.xml","form_type":"4"}},{"id":3358928,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2017 (right to buy)","published_at":"2019-11-26T21:08:12.000Z","date":"2019-11-22","kind":"grant","acquired":true,"shares":9999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date."}],"balance_after":9999,"derivative":{"exercise_price":119.13,"exercise_date":"2019-11-22","expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":9999},"source":{"system":"sec-edgar","filing":"0001735276-19-000110","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000110/edgardoc.xml","form_type":"4"}},{"id":3388740,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2019-10-24T20:04:20.000Z","date":"2019-10-22","kind":"exercise","acquired":false,"shares":58913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019.  The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":16.43,"expiration_date":"2019-12-09","underlying":"Common Stock","underlying_shares":58913},"source":{"system":"sec-edgar","filing":"0001735276-19-000094","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000094/edgardoc.xml","form_type":"4"}},{"id":3388739,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2019-10-24T20:04:20.000Z","date":"2019-10-23","kind":"other","acquired":false,"shares":5544,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were distributed in October 2019 to the reporting person from the \"Barry E. Greene Qualified Annuity Interest Trust\" (GRAT)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents remaining shares held by the \"Barry E. Greene Qualified Annuity Interest Trust\" (GRAT), of which Barry E. Greene is the sole Trustee"}],"balance_after":3486,"source":{"system":"sec-edgar","filing":"0001735276-19-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000094/edgardoc.xml","form_type":"4"}},{"id":3388738,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2019-10-24T20:04:20.000Z","date":"2019-10-23","kind":"other","acquired":true,"shares":5544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were distributed in October 2019 to the reporting person from the \"Barry E. Greene Qualified Annuity Interest Trust\" (GRAT)."}],"balance_after":58482,"source":{"system":"sec-edgar","filing":"0001735276-19-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000094/edgardoc.xml","form_type":"4"}},{"id":3388737,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2019-10-24T20:04:20.000Z","date":"2019-10-22","kind":"sale","acquired":false,"shares":58913,"price":89.99,"value":5301580.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019.  The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019."}],"balance_after":52938,"source":{"system":"sec-edgar","filing":"0001735276-19-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000094/edgardoc.xml","form_type":"4"}},{"id":3388736,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2019-10-24T20:04:20.000Z","date":"2019-10-22","kind":"exercise","acquired":true,"shares":58913,"price":16.43,"value":967940.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019.  The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019."}],"balance_after":111851,"source":{"system":"sec-edgar","filing":"0001735276-19-000094","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000094/edgardoc.xml","form_type":"4"}},{"id":3444733,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2016 (right to buy)","published_at":"2019-08-07T20:16:59.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date."}],"balance_after":25000,"derivative":{"exercise_price":42.22,"exercise_date":"2019-08-06","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001735276-19-000084","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000084/edgardoc.xml","form_type":"4"}},{"id":3444732,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2019-08-07T20:16:59.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":10000,"price":88.95,"value":889500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date."}],"balance_after":40000,"derivative":{"exercise_price":88.95,"exercise_date":"2019-08-06","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001735276-19-000084","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000084/edgardoc.xml","form_type":"4"}},{"id":3444731,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2019-08-07T20:16:59.000Z","date":"2019-07-11","kind":"other","acquired":true,"shares":46,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":3003,"source":{"system":"sec-edgar","filing":"0001735276-19-000084","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000084/edgardoc.xml","form_type":"4"}},{"id":3481742,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option","published_at":"2019-06-21T07:52:36.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 19, 2019, with the first quarterly installment vesting on September 19, 2019."}],"balance_after":15000,"derivative":{"exercise_price":7.54,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-038362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919119038362/doc4.xml","form_type":"4"}},{"id":3497443,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2016 (right to buy)","published_at":"2019-06-07T20:04:06.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. On June 6, 2019, the compensation committee of the Company determined the third performance criterion had been met on June 5, 2019 and the option vested as to one-quarter of the shares as of such date."}],"balance_after":18750,"derivative":{"exercise_price":42.22,"exercise_date":"2019-06-05","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001735276-19-000046","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000046/edgardoc.xml","form_type":"4"}},{"id":3497442,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2019-06-07T20:04:06.000Z","date":"2019-04-09","kind":"other","acquired":true,"shares":52,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":2957,"source":{"system":"sec-edgar","filing":"0001735276-19-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000046/edgardoc.xml","form_type":"4"}},{"id":3497441,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2019-06-07T20:04:06.000Z","date":"2018-10-18","kind":"other","acquired":true,"shares":21,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":2905,"source":{"system":"sec-edgar","filing":"0001735276-19-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000046/edgardoc.xml","form_type":"4"}},{"id":3496949,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2019-06-07T12:57:37.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on June 6, 2020, provided that the reporting person continues to serve as a director of the issuer through such date."}],"balance_after":25000,"derivative":{"exercise_price":5.43,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-035376","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919119035376/doc4.xml","form_type":"4"}},{"id":3623456,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option  (right to buy)","published_at":"2019-03-01T23:10:56.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2018. The reporting person also received 16,250 performance stock units that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":32500,"derivative":{"exercise_price":85,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001735276-19-000034","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527619000034/edgardoc.xml","form_type":"4"}},{"id":3805657,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2016 (right to buy)","published_at":"2018-09-28T20:54:33.000Z","date":"2018-09-27","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares\nsubject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":12500,"derivative":{"exercise_price":42.22,"exercise_date":"2018-09-27","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001735276-18-000071","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000071/edgardoc.xml","form_type":"4"}},{"id":3805656,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2018-09-28T20:54:33.000Z","date":"2018-09-27","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares\nsubject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":30000,"derivative":{"exercise_price":88.95,"exercise_date":"2018-09-27","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001735276-18-000071","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000071/edgardoc.xml","form_type":"4"}},{"id":3834876,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2018-08-23T20:15:28.000Z","date":"2018-08-21","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock.  One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee.  Effective August 21, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":20000,"derivative":{"exercise_price":88.95,"exercise_date":"2018-08-21","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001735276-18-000061","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527618000061/edgardoc.xml","form_type":"4"}},{"id":3844956,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Based Stock Option 2014 (right to buy)","published_at":"2018-08-14T23:14:51.000Z","date":"2018-08-10","kind":"grant","acquired":true,"shares":15875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award"}],"balance_after":47625,"derivative":{"exercise_price":96.45,"exercise_date":"2018-08-10","expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":15875},"source":{"system":"sec-edgar","filing":"0001325812-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000031/primary_doc.xml","form_type":"4"}},{"id":3844955,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Based Stock Option 2013 (right to buy)","published_at":"2018-08-14T23:14:51.000Z","date":"2018-08-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award."}],"balance_after":45000,"derivative":{"exercise_price":63,"exercise_date":"2018-08-10","expiration_date":"2023-12-18","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001325812-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000031/primary_doc.xml","form_type":"4"}},{"id":3844954,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-08-14T23:14:51.000Z","date":"2018-07-31","kind":"gift","acquired":true,"shares":9030,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The 9,030 shares were previously reported as directly beneficially owned. On 7/31/2018, the shares were contributed to the \"Barry E. Greene Qualified Annuity Interest Trust\" (GRAT). Barry E. Greene is the sole trustee."}],"balance_after":9030,"source":{"system":"sec-edgar","filing":"0001325812-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000031/primary_doc.xml","form_type":"4"}},{"id":3844953,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-08-14T23:14:51.000Z","date":"2018-07-10","kind":"other","acquired":true,"shares":29,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":2884,"source":{"system":"sec-edgar","filing":"0001325812-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000031/primary_doc.xml","form_type":"4"}},{"id":3844952,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-08-14T23:14:51.000Z","date":"2018-04-16","kind":"other","acquired":true,"shares":28,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":2855,"source":{"system":"sec-edgar","filing":"0001325812-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000031/primary_doc.xml","form_type":"4"}},{"id":3844951,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-08-14T23:14:51.000Z","date":"2018-01-17","kind":"other","acquired":true,"shares":17,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Managed Account"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program."}],"balance_after":2827,"source":{"system":"sec-edgar","filing":"0001325812-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000031/primary_doc.xml","form_type":"4"}},{"id":3844950,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-08-14T23:14:51.000Z","date":"2018-07-31","kind":"gift","acquired":false,"shares":9030,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52938,"source":{"system":"sec-edgar","filing":"0001325812-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581218000031/primary_doc.xml","form_type":"4"}},{"id":3880772,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option","published_at":"2018-06-29T07:42:19.000Z","date":"2018-06-27","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018."}],"balance_after":15000,"derivative":{"exercise_price":28.15,"expiration_date":"2028-06-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-039989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118039989/doc4.xml","form_type":"4"}},{"id":3887048,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2018-06-20T20:15:41.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 100% of the underlying shares on June 19, 2019, provided that the reporting person continues to serve as a director of the issuer through such date."}],"balance_after":17000,"derivative":{"exercise_price":18.8,"expiration_date":"2028-06-18","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-18-038757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1291963/000120919118038757/doc4.xml","form_type":"4"}},{"id":3920999,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Stock Option","published_at":"2018-05-23T07:35:38.000Z","date":"2018-05-21","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to these options vested in installments and were fully vested on 5/21/2009."}],"balance_after":0,"derivative":{"exercise_price":20.16,"expiration_date":"2018-05-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-032493","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118032493/doc4.xml","form_type":"4"}},{"id":3920998,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T07:35:38.000Z","date":"2018-05-21","kind":"tax_withholding","acquired":false,"shares":8727,"price":23.1,"value":201593.7,"ownership":{"direct":true},"balance_after":1273,"source":{"system":"sec-edgar","filing":"0001209191-18-032493","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118032493/doc4.xml","form_type":"4"}},{"id":3920997,"issuer":{"id":111987,"kind":"organization","name":"Acorda Therapeutics, Inc.","symbol":"ACOR"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-23T07:35:38.000Z","date":"2018-05-21","kind":"exercise","acquired":true,"shares":10000,"price":20.16,"value":201600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-18-032493","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008848/000120919118032493/doc4.xml","form_type":"4"}},{"id":3992856,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-03-16T21:05:38.000Z","date":"2018-03-14","kind":"sale","acquired":false,"shares":1300,"price":145.41,"value":189033.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Sale prices ranged from $145.16 to $145.79"}],"balance_after":61968,"source":{"system":"sec-edgar","filing":"0001553878-18-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000026/edgardoc.xml","form_type":"4"}},{"id":3992855,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-03-16T21:05:38.000Z","date":"2018-03-14","kind":"sale","acquired":false,"shares":9165,"price":144.67,"value":1325900.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices ranged from $144.14 to $145.13"}],"balance_after":63268,"source":{"system":"sec-edgar","filing":"0001553878-18-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000026/edgardoc.xml","form_type":"4"}},{"id":3992854,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-03-16T21:05:38.000Z","date":"2018-03-14","kind":"sale","acquired":false,"shares":8644,"price":143.58,"value":1241105.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $143.12 to $144.11"}],"balance_after":72433,"source":{"system":"sec-edgar","filing":"0001553878-18-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000026/edgardoc.xml","form_type":"4"}},{"id":3992853,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-03-16T21:05:38.000Z","date":"2018-03-14","kind":"sale","acquired":false,"shares":9217,"price":142.68,"value":1315081.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $142.12 to $143.11"}],"balance_after":81077,"source":{"system":"sec-edgar","filing":"0001553878-18-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000026/edgardoc.xml","form_type":"4"}},{"id":3992852,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-03-16T21:05:38.000Z","date":"2018-03-14","kind":"sale","acquired":false,"shares":7250,"price":141.74,"value":1027615.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $141.12 to $142.10"}],"balance_after":90294,"source":{"system":"sec-edgar","filing":"0001553878-18-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000026/edgardoc.xml","form_type":"4"}},{"id":3992851,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2018-03-16T21:05:38.000Z","date":"2018-03-14","kind":"sale","acquired":false,"shares":2884,"price":140.43,"value":405000.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 11, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $140.00 to $140.95"}],"balance_after":97544,"source":{"system":"sec-edgar","filing":"0001553878-18-000026","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000026/edgardoc.xml","form_type":"4"}},{"id":4015847,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option  (right to buy)","published_at":"2018-03-05T22:48:26.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the time-vested portion of the reporting person's Annual Stock Option Award for 2017. The reporting person also received 30,000 options to purchase shares of ALNY common stock that will vest upon the achievement of three specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months"}],"balance_after":30000,"derivative":{"exercise_price":119.13,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001553878-18-000009","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387818000009/edgardoc.xml","form_type":"4"}},{"id":4123793,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2016 (right to buy)","published_at":"2017-12-21T21:37:26.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock.  One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee.  Effective December 20, 2017, the compensation\ncommittee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":6250,"derivative":{"exercise_price":42.22,"exercise_date":"2017-12-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001325812-17-000036","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000132581217000036/edgardoc.xml","form_type":"4"}},{"id":4169043,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Performance Stock Option 2015 (right to buy)","published_at":"2017-11-08T22:25:19.000Z","date":"2017-11-06","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock.  One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee.  Effective November 6, 2017, the compensation committee of the Company determined the first performance criterion had been met and the option vested as to one-quarter of the shares."}],"balance_after":10000,"derivative":{"exercise_price":88.95,"exercise_date":"2017-11-06","expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001553878-17-000063","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000063/edgardoc.xml","form_type":"4"}},{"id":4192321,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":36009,"kind":"person","name":"Greene Barry E","position":1,"cik":"0001291963","reported_name":"Greene Barry E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-04T23:45:34.000Z","date":"2017-10-02","kind":"exercise","acquired":false,"shares":85316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares each successive three month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":21.35,"expiration_date":"2018-12-08","underlying":"Common Stock","underlying_shares":85316},"source":{"system":"sec-edgar","filing":"0001553878-17-000054","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000155387817000054/primary_doc.xml","form_type":"4"}}],"next_cursor":"2017-10-04T23:45:34.000000Z,4192321"}